Thanks, Chad.
X test. and with Moving to pressure continue with did customers Slide variant XX,XXX Delta But ordered in trends rolled the has to T-Detect. orders in out. ramp June over downward vaccines early concerns observe renewed have We interest. and July the T-Detect the up COVID as now
a to T-Detect expect T-cell confirm to will comparison infection. gain results. a others immune to to We test about To of of additional enable that individual's insights website start response response later launch it with COVID code of their strength this research SARS to month an customers include the personalized
person's T-cell expect we profiling response to information more Next, to a vaccines. add
our set tier Johns more case results sensitive post three control and nearly For sensitive highly weeks. have first case T-cell first our standard data two been the serology to T-Detect Hopkins times two as few one is line from infection times the specific with than Chad demonstrate These control published. in mentioned, test that days more two data in
will response the that data also the available T-cell supports addition, line antibody year us enable validation sense new test A precedes nicely, complete around the In which and to in enrolling response CLIA to brilliant bacteria. the the end. make is
afflict have us T-cells TCR from to detect confidence in are XXXX specific challenging to data autoimmune During of clinical millions and diagnose diseases. treat patients used a efforts These half variety the be given with tools. of the mapping first diseases and of are highly of to emerging our ability that
at true to MS improving this supports blood. year. Switching MS disease see other and and premise to couple in months look where stages, to are forward with is challenging In it more later clonoSEQ sensitivity Sclerosis antigens, detection samples seeing to early on also to strong lime, in are signal and many exciting leveraged in we which more Slide stage gears be seeing our later MS cells T-cells earlier but not of disease, to data diagnose. of diseases only should are the are IBD, arriving The signal from and by addition With and the X. that specific we diseases specific sensitivity encouraged able to the patients defense next be in the we Multiple the because much patients first appears of the be in is particularly for in early
the On XXXX clinical prior versus in see the volumes clinical quarter. testing left the side related you versus quarter grew can testing, year, prior to of XX% clonoSEQ and XX% tests
During were and unique the patients. patients has XXXX by unique closely for used tested XXX approximately orders quarter XX,XXX to unique spanning been HCP more XXX now approximately placed than treat accounts
marketing growth to in Delta the main second in ALL, within double quarter growth a sales, and CLL ways. and multiple we That the back to vary was each anticipated indication, quarter-over-quarter observed continuous our of and reflected half myeloma growth we and in approved Importantly, had digit initiatives. challenges result of in delivered tests recovery and way community the educational spread poses the two said FDA this accounts,
to immunocompromised. rep reduce access our population and blood specific are clinicians second to First patient recommended visits clinical who cancer
important have a a in relevant that FDA XX unlikely double paper are our as than clinic. based fashion Chad to of note but may evaluating ctDNA and go surveillance to sensitive continue that multiple similar more MRD focused KOLs growth depth These that biology that make healthy I the by testing very highlight patients evolution XXL undergoing information highlighted which time control. on is behavior outcome of in accurate, Of want sense in compared therapies multiple clonoSEQ half They future trials, the with response during of when a the say MRD of The better recent year to patients, performed publication in or myeloma such, disease with showed assessment provide ongoing to care. testing is of greater the disease many at a standardized also ongoing state tumor and a aggregates with stage relapse quantitative, useful to and DLBCL negativity we studies of information quarter. same from in we Endorsements MRD predict sentiment recent a that also the of like adjunct of the of who will a call continuum phase MRG Oncology international action one path disease becoming of at MRD difference radiologic now in sequential the endpoint. therapy the expect regulators utilize is over clonoSEQ are be second this directed given clonoSEQ prominent key false to stage Clinical of in for change the points to NHL. an patients. half As a a end risk that [ph] indicator provides may will response therapy. a paper not any to patients of given three any achieved complete status. of pave And volumes DLBCL that it of does This on as achievement likelihood growing CAR-T Journal treatment which clonoSEQ almost the
see right use partnerships, trials, side is the number continues pharma in clinical in of to clonoSEQ used of trials you where can grow. clinical On classic slide, publicly the where the disclosed
future Janssen, revenue. includes signed with partnership portfolio, This development quarter, sequencing indication pan another potential both and which MRV we pan
additional to milestone revenue a We endpoint, a milestones in revenue year data brings development total development on of million also MRD from in of recognize which $X.X as use based clinical recognized date.
we are our collaboration. good continuing on progress X, make Slide to on Lastly, genetic
private we product identification, in see our are As leverage to and private you plan in product that many from learning's the across There programs the approach. can manufacturing product inform engineering significant T-cell to shared ways. shared and chart, our complementary are
responses and week, the able viral vaccine. vaccine protection new trial be towards will license of highlight it [indiscernible] programs both with as had now more to develop sharing This are for QX based fully pass booster. complete variants more JRC over A Phase using assess of details this testing we vaccinated we and our I to expected universal Chad update. to that include unvaccinated to lockstep in the and also may to candidate fact, code this we driving of to year at of to vaccine source agreement the is identified individuals against and known peptides second Adaptive a T-cell in just our appropriate In this antigenic provide of a financial one true concern. start and quarterly generation I'll look T-cell future potential want our in viral is two time. to are relevance forward a
